Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Average Recommendation of "Hold" by Brokerages

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) have received a consensus recommendation of "Hold" from the seven research firms that are covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $4.94.

Several equities research analysts recently weighed in on IRWD shares. Zacks Research lowered Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday, September 5th. Wall Street Zen upgraded Ironwood Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 9th.

Ironwood Pharmaceuticals Trading Up 8.3%

NASDAQ:IRWD traded up $0.10 on Monday, hitting $1.25. 760,511 shares of the company's stock traded hands, compared to its average volume of 2,720,066. The company has a market cap of $202.23 million, a PE ratio of -24.90 and a beta of 0.33. Ironwood Pharmaceuticals has a 1 year low of $0.53 and a 1 year high of $5.13. The firm has a 50-day moving average price of $0.96 and a 200-day moving average price of $0.98.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.16. The business had revenue of $85.24 million during the quarter, compared to analyst estimates of $62.02 million. Ironwood Pharmaceuticals had a negative return on equity of 2.46% and a negative net margin of 2.25%. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts forecast that Ironwood Pharmaceuticals will post 0.1 EPS for the current fiscal year.

Institutional Trading of Ironwood Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Ironwood Pharmaceuticals during the fourth quarter valued at approximately $36,000. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Ironwood Pharmaceuticals during the fourth quarter valued at approximately $59,000. Raymond James Financial Inc. bought a new stake in shares of Ironwood Pharmaceuticals during the fourth quarter valued at approximately $68,000. Tower Research Capital LLC TRC increased its position in shares of Ironwood Pharmaceuticals by 1,130.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 17,521 shares of the biotechnology company's stock valued at $78,000 after purchasing an additional 16,097 shares during the period. Finally, Hsbc Holdings PLC increased its position in shares of Ironwood Pharmaceuticals by 88.9% during the fourth quarter. Hsbc Holdings PLC now owns 20,886 shares of the biotechnology company's stock valued at $91,000 after purchasing an additional 9,828 shares during the period.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.